姓名：蒋筱莹，副教授，硕士生导师

办公电话：无

邮箱：xyjiang@hznu.edu.cn

指导专业：药学（药物化学）

课题组网站：无

【研究领域】

1、抗肿瘤候选药物研发

2、抗皮肤病候选药物研发

【主讲课程】

1、药物化学（本科生）

2、药物化学实验（本科生）

3、类药性研究（本科生）

4、药物临床前研究（本科生）

5、药物发现与开发（研究生）

6、新药研发基本原理与AI赋能（研究生）

【教育和工作经历】

2010年9月—2014年6月：浙江工业大学，药学，学士

2014年9月—2017年3月：浙江工业大学，药学，硕士

2016年8月—2016年11月：King’s college London, Faculty of life science & medicine, Institute of pharmaceutical science, Academic visitor

2017年9月—2020年7月：浙江工业大学，药物化学，博士

2020年10月—2022年10月：中南大学，化学，博士后

2023年1月—2024年12月：杭州师范大学，药学院，助理研究员

2024年12月—至今：杭州师范大学，药学院，副教授

【学术简介（限200字）】

主要从事抗肿瘤、抗炎、抗皮肤病、抗AD候选药物研发，AI辅助药物发现等研究工作。主持国家自然科学基金1项，参与国家自然科学基金2项、浙江省自然科学基金1项。目前以第一作者和通讯作者在Journal of Advanced Research, Journal of Medicinal Chemistry, Medicinal Research Reviews, European Journal of Medicinal Chemistry, Journal of Enzyme Inhibition and Medicinal Chemistry, Bioorganic & Medicinal Chemistry, Bioorganic Chemistry, Advance Therapeutics, Chinese Journal of Integrative Medicine等国内外学术刊物发表SCI论文20余篇；授权发明专利10项。

【主持教学科研项目】省部级以上

1、国家自然科学基金青年项目（2024年1月—2026年12月）：新型ALA-HPO衍生物的发现及其光动力-化疗协同抗黑色素瘤活性研究，30万，项目负责人。

【代表性论著】

[1] Yinyan Sun, Jiahui Wang, Wenchao Chen, Hao Wen, Meiling Feng, Xiaotian Niu, Jia Zhi, Shengjie Hu, Shan Wang, Hong Cai, Bin Ju, Keda Yang, Xiaoying Jiang*, Renren Bai*. Strategy and efficiency-redefined discovery of novel nanomolar tyrosinase inhibitors: AI de novo molecular generation + expert-guided structural optimization. Journal of Advanced Research, 2025, 10.1016/j.jare.2025.12.041.

[2] Jiahui Wang1, Yinyan Sun1, Xiaoying Jiang1, Hao Wen, Hong Cai, Meiling Feng, Xiaotian Niu, Shan Wang, Jia Zhi, Junchao Xie, Rui Wang, Wenchao Chen*, Renren Bai*. Discovery of novel dihydroxyphenol tyrosinase inhibitors for treatment of pigmentation: From enzyme screening to three-dimensional human skin melanin evaluation. Journal of Medicinal Chemistry, 2025, 68(22), 24047-24074.

[3] Xiaoying Jiang*, Liuxin Lu, Junjie Li, Jing Jiang, Jiapeng Zhang, Shengbin Zhou, Hao Wen, Hong Cai, Xinyu Luo, Zhen Li, Jiahui Wang, Bin Ju*, Renren Bai*. Synthetically feasible de novo molecular design of leads based on a reinforcement learning model: AI-assisted discovery of an anti-IBD lead targeting CXCR4. Journal of Medicinal Chemistry, 2024, 67(12), 10057-10075.

[4] Hong Cai, Wenchao Chen, Jing Jiang, Hao Wen, Xinyu Luo, Junjie Li, Liuxin Lu, Rui Zhao, Xinhua Ni, Yinyan Sun, Jiahui Wang, Zhen Li, Bin Ju*, Xiaoying Jiang*, Renren Bai*. Artificial intelligence-assisted optimization of antipigmentation tyrosinase inhibitors: De novo molecular generation based on a low activity lead compound. Journal of Medicinal Chemistry, 2024, 67(9), 7260-7275.

[5] Liuxin Lu, Junjie Li, Xiaoying Jiang*, Renren Bai*. CXCR4/CXCL12 axis: “old” pathway as “novel” target for anti-inflammatory drug discovery. Medicinal Research Reviews, 2024, 44(3), 1189-1220.

[6] Hong Cai, Hao Wen, Junjie Li, Liuxin Lu, Wenxuan Zhao, Xiaoying Jiang*, Renren Bai*. Small-molecule agents for treating skin diseases. European Journal of Medicinal Chemistry, 2024, 268, 116269.

[7] Xiaoying Jiang, Liuxin Lu, Jiahui Wang, Meng Yu, Rui Wu, Rui Zhao, Hao Wen, Renren Bai*. Discovery of dibenzyl amide derivatives as novel CXCR4 modulators against inflammatory bowel disease. European Journal of Medicinal Chemistry Reports, 2024, 10, 100134.

[8] Xiaoying Jiang, Liping Shi, Junlong Zhu, Renren Bai*, Tian Xie*. Elemene antitumor drugs development based on “Molecular Compatibility Theory” and clinical application: A retrospective and prospective outlook. Chinese Journal of Integrative Medicine, 2024, 30 (1), 62-74.

[9] Xiaoying Jiang, Kaiyu Wu, Xiang-Yang Ye, Tian Xie, Pengfei Zhang*, Benjamin E. Blass*, Renren Bai*. Novel druggable mechanism of Parkinson’s disease: Potential therapeutics and underlying pathogenesis based on ferroptosis. Medicinal Research Reviews, 2023, 43(4), 872-896.

[10] Xiaoying Jiang, Kaiyu Wu, Renren Bai*, Pengfei Zhang*, Yi Zhang*. Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities. European Journal of Medicinal Chemistry, 2022, 229, 114085.

[11] Xiaoying Jiang, Jianan Guo, Changjun Zhang, Jinping Gu, Tao Zhou, Renren Bai*, Yuanyuan Xie*. Discovery of benzamide-hydroxypyridinone hybrids as potent multi-targeting agents for the treatment of Alzheimer’s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36 (1), 2045-2054.

[12] Xiaoying Jiang, Tao Zhou, Renren Bai*, Yuanyuan Xie*. Hydroxypyridinone-based ironchelators with broad-ranging biological activities, Journal of Medicinal Chemistry, 2020, 63(23), 14470-14501.

[13] Xiaoying Jiang, Jianan Guo, Yangjing Lv, Chuansheng Yao, Changjun Zhang, Zhisheng Mi, Yuan Shi, Jinping Gu, Tao Zhou, Renren Bai*, Yuanyuan Xie*. Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity. Bioorganic & Medicinal Chemistry, 2020, 28, 115550.

【荣誉与奖励】省部级以上

【授权专利及转化】

[1] 白仁仁, 蒋筱莹, 陈文超, 文豪, 孙寅炎, 王嘉辉. 酪氨酸酶抑制剂及其制备方法和应用, 2025-06-13, 中国, CN202510347775.4

[2] 白仁仁, 居斌, 蒋筱莹, 李俊杰. CXCR4拮抗剂及其制备方法和应用, 2025-08-29, 中国, CN202311563469.1

[3] 白仁仁, 谢恬, 叶向阳, 蒋筱莹. 双苄酰胺类CXCR4拮抗剂及其制备和应用, 2024-02-09, 中国, CN202111180420.9

[4] 谢媛媛, 蒋筱莹, 郭嘉楠, 张雨佳. 具潜在多靶点抗AD活性的甲酰胺吡啶酮类铁螯合剂衍生物及其制备方法与应用, 2022-11-25, 中国, CN202010724446.4 

[5] 谢媛媛, 蒋筱莹, 姚传胜, 郭嘉楠, 吕杨静. 具潜在抗AD活性的香豆素杂合吡啶酮酰胺衍生物及其制备方法与应用, 2021-07-27, 中国, CN201911085756.X 

[6] 谢媛媛, 蒋筱莹, 甘兵, 米治胜, 张长俊, 黄应益, 白仁仁. 一种含氨基的羟基吡啶酮类化合物的合成方法, 2020-11-13, 中国, CN201810102188.9 

[7] 谢媛媛, 蒋筱莹, 甘兵, 米治胜, 白仁仁, 林玉燕, 姚传胜. 香豆素/吡啶酮杂合衍生物及其制备方 法与应用, 2020-10-09, 中国, CN201811635128.X

[8] 谢媛媛, 蒋筱莹, 郭冬艳, 王文慧, 米治胜, 金婷婷. 一种5-氨基四氮唑类化合物的制备方法, 2018-08-21, 中国, CN201510884617.9